Formulation screening and development for first-in-animal efficacy and safety testing is not a trivial task; not only does a dose-vehicle need to be identified that can enable the administration of the drug at a wide range of concentrations, it also needs to be safe from an excipient tolerability and toxicity stand-point for the desired route of administration, test species and in-life dosing duration. This adds extra complication and can often be the cause for build up of bottlenecks between identifying in vitro hits and obtaining in vivo results.
Rapid Dose Vehicle Identification to Expedite Leads and Reduce Cost
Funded through a multi-year grant from the UK Regional Development Agency, Kuecept has developed the award winning Solent™ platform, which is a cost-effective and rapid dose vehicle screening service combining process miniaturisation, excipient safety profiling and expert formulation design. Used at the correct time it provides an inexpensive way of drastically improving the chances of your poorly soluble discovery API becoming a viable clinical drug candidate.
Click here to learn more about this screening service.
A Proven Technology
To date, Solent™ has been successfully used by over 75 pharmaceutical, biotechnology and academic laboratories around the world on over 140 candidate molecules. This has resulted in over 30 compounds being progressed into first-in-human clinical studies for both oral and parenteral applications.
"Kuecept’s Solent™ platform has enabled us to speed up the selection of our poorly soluble discovery candidates and progress our lead molecules into preclinical studies with robust and safe dosing vehicles".